Literature DB >> 2476070

Interaction of lysosomal cysteine proteinases with alpha 2-macroglobulin: conclusive evidence for the endopeptidase activities of cathepsins B and H.

R W Mason1.   

Abstract

The lysosomal cysteine proteinases, cathepsins B, H, and L, were all shown to bind to alpha 2-macroglobulin. The bound enzymes remained active against low-molecular-weight synthetic substrates and bound the active-site-directed inhibitor, benzyloxycarbonyl-125I-Tyr-Ala-diazomethane. Binding of the radiolabeled inhibitor to high-molecular-weight protein on sodium dodecyl sulfate polyacrylamide gels indicated that a proportion of the enzymes was covalently bound to alpha 2-macroglobulin. Cleavage fragments of alpha 2-macroglobulin of Mr 92,000 and 86,000 were seen for cathepsins B, H, and L, indicating cleavage in the bait region. Binding and cleavage were observed for both single-chain and two-chain forms of cathepsin B from human, ox, and pig livers, showing that all active forms of cathepsins B, H, and L are endopeptidases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476070     DOI: 10.1016/0003-9861(89)90495-5

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  10 in total

1.  A model to explain the pH-dependent specificity of cathepsin B-catalysed hydrolyses.

Authors:  H E Khouri; C Plouffe; S Hasnain; T Hirama; A C Storer; R Ménard
Journal:  Biochem J       Date:  1991-05-01       Impact factor: 3.857

2.  Demonstration by electrospray mass spectrometry that the peptidyldipeptidase activity of cathepsin B is capable of rat cathepsin B C-terminal processing.

Authors:  A D Rowan; R Feng; Y Konishi; J S Mort
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

Review 3.  Cathepsin B and its endogenous inhibitors: the role in tumor malignancy.

Authors:  B F Sloane; K Moin; E Krepela; J Rozhin
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

4.  Human tumour cathepsin B. Comparison with normal liver cathepsin B.

Authors:  K Moin; N A Day; M Sameni; S Hasnain; T Hirama; B F Sloane
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

5.  Human sputum cathepsin B degrades proteoglycan, is inhibited by alpha 2-macroglobulin and is modulated by neutrophil elastase cleavage of cathepsin B precursor and cystatin C.

Authors:  D J Buttle; M Abrahamson; D Burnett; J S Mort; A J Barrett; P M Dando; S L Hill
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

6.  Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse.

Authors:  Melanie M Ivancic; Edward L Huttlin; Xiaodi Chen; Jennifer K Pleiman; Amy A Irving; Adrian D Hegeman; William F Dove; Michael R Sussman
Journal:  J Proteome Res       Date:  2013-08-08       Impact factor: 4.466

7.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues.

Authors:  M R Buck; D G Karustis; N A Day; K V Honn; B F Sloane
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

8.  Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase.

Authors:  M Abrahamson; R W Mason; H Hansson; D J Buttle; A Grubb; K Ohlsson
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

9.  Mutant cells selected during persistent reovirus infection do not express mature cathepsin L and do not support reovirus disassembly.

Authors:  G S Baer; D H Ebert; C J Chung; A H Erickson; T S Dermody
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 10.  Practical context of enzymatic treatment for wound healing: A secreted protease approach (Review).

Authors:  María Isabela Avila-Rodríguez; David Meléndez-Martínez; Cuauhtemoc Licona-Cassani; José Manuel Aguilar-Yañez; Jorge Benavides; Mirna Lorena Sánchez
Journal:  Biomed Rep       Date:  2020-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.